Search Results

Explore Dr. GPCR Ecosystem

postdoctoral training, I joined one of the labs that participated in Latrophilins’ discovery, the lab of Dr Thomas Südhof, but did not start working on them right away.

Explore Dr. GPCR Ecosystem

Dr.

In reality, something more subtle starts to shift. 👉 Decision-making changes. Plans that once felt flexible start to feel constrained. Roadmaps stop being tools for choice and start becoming tools for justification. Strategic takeaway 👉 For biotech founders , financial failure rarely starts with an empty bank account It starts when financial control fades without being noticed . 👉 The key shift is not better reporting

doesn’t immediately tell them who it’s for, why it matters, and what makes it different, then they start They have to guess why it matters, what the application is, and whether it fits. ✅ Start with relevance People start leaning in. You stop explaining. People start connecting the dots for you. 👉 This is what clarity creates. Start refining your message. Ready to Break Your Bottlenecks?

struggling to predict structures from scratch, Alessandro and others could now use AI-generated models as starting “…now you have a plethora of 400 models that you can start with molecular dynamics, docking, virtual Start with our GPCR training program and get hands-on with virtual tools shaping the future of drug discovery

Yet over time, alignment fades, and decisions start to feel disconnected. 👉 Many founders ask why biotech startups fail  not after a collapse, but when the company starts to feel harder to run without a clear decisions The turning point for many biotech startups comes when strategy stops being a document and starts Instead of adding more work to feel safer, teams start designing fewer experiments with sharper intent trusts execution because work is clearly tied to strategic intent. ✅ The company stops reacting and starts

When too many priorities advance in parallel, focus starts to diffuse. Resources stretch. When Everything Is Strategic, Nothing Is Decisive 👉 Strategic overload starts with reasonable decisions From the outside, investors start to ask subtle questions. What is the real bet? Yet the hardest strategic decisions are rarely about starting something new. diluted commitment. 👉 Biotech fundraising reflects the structure of your strategy long before you start

Where Biotech Misalignment Starts 👉 Most misalignment doesn’t start with conflict. It starts with silence. You assume your CSO knows where you’re headed. Your BD person starts framing it for a niche diagnostic use. The board expects an IND package. Real biotech traction starts when decisions are driven by shared strategy, not disconnected deliverables tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

Starting From Zero: Growing With a Mentor When Alessandro joined Prof. At the start it was difficult, because you see all these projects and you think, ah, I don’t know… but

consistency: Can you show that your process will be scalable, repeatable, and GMP-compliant from the start Reverse Engineering Your Path to FDA Approval Most biotech development plans are built forward : start They start by asking: What would FDA approval actually require from us, and what decisions need to reflect Instead of collecting interesting data, you start collecting strategic evidence . tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

New initiatives start. Additional questions are explored. Prevents Drift Before It Becomes Failure Preventing this form of biotech startup failure  does not start It starts with a leadership shift. ✅ Founders must stop evaluating decisions individually and start managing or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start

. ✅ Founders start adapting their message in real time , trying to meet expectations instead of setting Instead of starting from depth, it starts from relevance. better wording . 👉 Once positioning is decided, conversations stop revolving around explanation and start or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start

Teams start planning around delays BD and investor messaging drifts Timelines become aspirational rather “we hope next year is better” → to “our cadence ensures it will be.” ✅ If you want a stronger 2025, start tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

’t Feel Until It’s Too Late 👉 Every early-stage biotech reaches a moment where the science finally starts interesting but unready.” 3️⃣ Internal Alignment Frays When “the science” drives everything, different teams start tradeoffs, or simply feeling stuck, this session will get you unstuck, fast. 👉 Book a 1:1 consult and start

. 👉 Start your journey with Terry’s foundational series Unlock "Unique Role of Pharmacology" now

They fail when the pressure of fundraising slowly starts reshaping how decisions are made , long before Decisions stop being evaluated based on long-term leverage and start being filtered through a single What helps the raise starts to matter more than what strengthens the company. 👉 In practice, biotech Scientific nuance starts to feel inconvenient. or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start

on both sides of the biotech fundraising table Why biotech fundraising breaks before diligence even starts 👉 This is where intellectual property gaps start to matter. the IP does not map cleanly to how the company plans to generate returns, the fundraising narrative starts tradeoffs, or simply feeling stuck, this session will get you unstuck — fast. 👉 Book a 1:1 consult and start

If you're starting out in pharmacology, this lesson gives you the interpretive tools to ask smarter questions

“Companies started shutting down neuroscience and GPCR programs. But I stayed,” Sokhom said.

But Sokhom’s journey started differently.

With alignment, execution starts to feel lighter, faster, and more coherent. Strong early decision-making starts with intention. 👉 Founders who take control of this phase do not or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start

the extracellular binding site of the GPCR, the protein changes into its active conformation , which starts to study therapeutic targets are fluorescent ligands , which are very useful in GPCR drug discovery, starting

schools and universities, research centers, governmental institutions, or private companies) Deadlines Start

study will evaluate TRV045 safety, tolerability, and PK in healthy volunteers Enrollment expected to start

Disciplined ambition starts with a simple shift in thinking. or simply feeling stuck, this session will help you get unstuck quickly. 👉 Book a 1:1 consult and start

fluorescent antagonist (CELT-327) was added to HCT116 cells (colon cancer cell line), detectable fluorescence starting for GPCR assays using Fluorescent Probes The preparation of the cellular system is the most common starting

Starting from a high-throughput screening hit, we describe the iterative optimization of a chemical series

Starting from previously reported intracellular CCR2 antagonists, several tetramethylrhodamine (TAMRA